Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17876358 | 0.86 | ALDH1A1 (0.36) | MEN1KMT2ANPC1KDM4EALDH1A1 | |
| SCHEMBL17876377 | 0.63 | KMT2A (0.39) | MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL26035484 | 0.63 | KMT2A (0.32) | MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL17876385 | 0.62 | KMT2A (0.33) | MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL8310257 | 0.59 | ALOX15 (0.44) | MEN1KMT2ANPC1KDM4EHPGD | |
| SCHEMBL17876389 | 0.57 | ALDH1A1 (0.38) | KMT2AALDH1A1 | |
| SCHEMBL28774082 | 0.57 | ALPG (0.48) | MEN1KMT2AKDM4EMAPK1 | |
| SCHEMBL29769730 | 0.56 | KDM4E (0.48) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL28726401 | 0.56 | KDM4E (0.48) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL28726451 | 0.56 | KDM4E (0.48) | MEN1KMT2AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185745-A1 | ANALOGS OF VINAXANTHONE AND XANTHOFULVIN, METHODS OF SYNTHESIS, AND METHODS OF TREATMENTS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185745-A1 | ANALOGS OF VINAXANTHONE AND XANTHOFULVIN, METHODS OF SYNTHESIS, AND METHODS OF TREATMENTS THEREOF | VAT1, NQO1, VARS1 | MEN1 1749/4885KMT2A 2453/4885NPC1 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.